


Amendments to the Claims

1-2. (Cancelled)


3. (Currently amended) A ~~pharmaceutical composition used~~ method for treatment or prevention of a ~~brain injury comprising, which comprises~~ administering an effective amount of an antagonist for prostaglandin D receptor as ~~an effective ingredient~~ to a patient in need thereof.

4. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 3, wherein the antagonist for a prostaglandin D receptor is (\pm)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)-hydantoin, (+)-(3R)-3-(4-fluorobenzenesulfonamide)-1,2,3,4-tetrahydrocarbazol-9-propionic acid, (Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid, (Z)-7-[(1R,2R,3S,5S)-2-(benzo[b]thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid ~~and, or a pharmaceutically acceptable salt thereof and, or a hydrate thereof.~~

5. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (I)




[[I]] wherein,




R is hydrogen, alkyl, alkoxy, halogen, hydroxyl, acyloxy or optionally substituted arylsulfonyloxy; X is hydrogen or alkyl; and a double bond of an α -chain is in an E-configuration or a Z-configuration ~~[[]]~~ or a pharmaceutically acceptable salt or a hydrate thereof.

6. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA)



~~[[]]~~ wherein R and X have the same meanings as defined already is hydrogen, alkyl, alkoxy, halogen, hydroxyl, acyloxy or optionally substituted arylsulfonyloxy; X is hydrogen or alkyl; and a double bond of an α -chain is in an E-configuration or a Z-configuration ~~[[]]~~ or a pharmaceutically acceptable salt or a hydrate thereof.

7. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA-a)



~~[[]]~~ wherein R and X have the same meanings as defined already is hydrogen, alkyl, alkoxy, halogen, hydroxyl, acyloxy or optionally substituted arylsulfonyloxy; X is hydrogen or alkyl; and a double bond of an α -chain is in an E-configuration or a Z-configuration ~~[[]]~~ or a pharmaceutically acceptable salt or a hydrate thereof.

8-9. (Cancelled)

10. (Currently amended) A method for treatment of a brain injury comprising, which comprises administration of an effective amount of a prostaglandin D receptor antagonist ~~of an effective dose~~ to a patient in need thereof.

11-13. (Cancelled)